Milestone Scientific

Milestone Scientific, Inc. is a biomedical technology research and development company, which patents, designs, and develops diagnostic and therapeutic injection technologies and instruments. It operates through the following segments: Dental, Medical, and Corporate. The Corporate segment refers to executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities, and public company compliance costs. Its solutions include CompuFlo Epidural, CathCheck Verification System, and Single Tooth Anesthesia System. The company was founded on August 17, 1989 and is headquartered in Roseland, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Milestone Scientific reports Q1 revenue, eyes international expansion opportunities

Milestone Scientific's Q1 2024 performance showed revenue over $2.2 million with improved gross margins.
The company's focus on customer relationships and reimbursement strategies is a key strength.
Challenges include revenue decrease and the need for endorsements in the medical space.
Opportunities lie in international expansion, market penetration goals, and increased marketing efforts.

Milestone Scientific reports improved Q2 performance amidst revenue challenges

Milestone Scientific showcased financial improvements in Q2 2024 despite a revenue decrease, with a focus on enhancing operational efficiency and achieving positive cash flow.
The company's strategic partnerships, international expansion plans, and commitment to innovation through intellectual property enhancements signal a path for future growth and market competitiveness.
While facing challenges in revenue generation and operational clarity, Milestone Scientific's strong balance sheet and market positioning offer opportunities for sustained growth and profitability.

Milestone Scientific reports revenue growth and strategic partnerships in Q3

Milestone Scientific shows promising revenue growth and operational improvements in Q3 2024, driven by strong Dental division performance and international sales.
Strategic partnerships and a solid financial position enhance market reach and provide a foundation for future growth.
Challenges include reducing net losses, driving market adoption of CompuFlo, and navigating Medicare coverage expansion, while opportunities exist in reimbursement initiatives and market expansion post-approvals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Milestone Scientific, Inc. (MLSS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Milestone Scientific, Inc. (MLSS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

ROSELAND, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced that Arjan Haverhals, CEO of Wand Dental and President of Milestone Scientific, will be presenting at the Q1 Virtual Investor Summit on March 24th.

Milestone Scientific to Present at the Q1 Virtual Investor Summit

Milestone Scientific Inc (NYSEAMERICAN:MLSS) announced Wednesday it has received a Notice of Allowance from the European Patent Office as the company seeks to develop a device for ultrasound-guided peripheral nerve block (PNB) procedures. The patent office's decision allows for the company to combine minimum intensity of nerve stimulation (MIS) and real-time injection pressure (IP) monitoring by utilizing Milestone's CompuFlo instrument and associated DPS Dynamic Pressure Sensing Technology to optimize needle tip location in PNB procedures.

Milestone Scientific receives notice of allowance for European patent as company seeks to develop device for ultrasound-guided peripheral nerve block procedures

ROSELAND, N.J., March 10, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it has received Notice of Allowance from the European Patent Office (EPO) combining minimum intensity of nerve stimulation (MIS) and real-time injection pressure (IP) monitoring utilizing Milestone's CompuFlo® instrument and associated DPS Dynamic Pressure Sensing Technology® to optimize needle tip location in ultrasound-guided peripheral nerve block (PNB) procedures. The technology was developed in conjunction with Dr. Olivier Choquet from the Lapeyronie University Hospital Montpellier France, a renowned expert in peripheral nerve block procedures, and Dr. Mark Hochman, D.D.S., Inventor and Clinical Director for Milestone Scientific.

Milestone Scientific Receives Notice of Allowance for European Patent Related to Combination of Nerve Stimulation and DPS Dynamic Pressure Sensing Technology® to Optimize Needle Tip Location in Ultrasound-Guided PNB Procedures

Milestone Scientific Inc (NYSEAMERICAN:MLSS), a leading developer of computerized drug delivery instruments that provide virtually painless and precise injections, said Tuesday it has begun selling CompuFlo/CathCheck disposables to the Medical University of South Carolina (MUSC).  The MUSC University Medical Center is a nationally recognized and leading health sciences university, recently ranked as the number one hospital in South Carolina, the company noted.

Milestone Scientific starts selling CompuFlo/CathCheck disposables to the Medical University of South Carolina

ROSELAND, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it has begun selling CompuFlo® / CathCheck™ disposables to the Medical University of South Carolina (MUSC). The MUSC University Medical Center is a nationally recognized and leading health sciences university, recently ranked as the number one hospital in South Carolina. MUSC Health owns and operates eight hospitals and provides patient care throughout the state of South Carolina.

Milestone Scientific Inc. Commences Sales of CompuFlo® / CathCheck™ Disposables to the Nationally Recognized Medical University of South Carolina

Milestone Scientific Inc (NYSEAMERICAN:MLSS) announced Wednesday it had received a Notice of Allowance from the US patent office for its new CompuPulse System. The CompuPulse System integrates Milestone's CompuWave technology with a manual syringe, and the Notice of Allowance relates to a method and apparatus that detects a pulsatile pressure waveform to more easily perform the identification of anatomical target regions.

Milestone Scientific receives Notice of Allowance from US patent office for new CompuPulse system

CompuPulse integrates CompuWave™ technology with a manual syringe to verify needle and catheter placement CompuPulse integrates CompuWave™ technology with a manual syringe to verify needle and catheter placement

Milestone Scientific Inc. Announces Breakthrough CompuPulse System and Receives Notice of Allowance for U.S. Patent

Milestone Scientific Inc (NYSEAMERICAN:MLSS) said it has begun selling its CompuFloEpidural Instrument and related disposables to the University Hospital of Würzburg (UHW) in Germany. “We appreciate the decision of the University of Wurzburg, in association with Dr Kranke and his team, to purchase our CompuFlo Epidural System.

Milestone Scientific begins sales of CompuFlo epidural instruments and disposables to University Hospital of Wurzburg

ROSELAND, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced that it has begun selling its CompuFlo® Epidural Instrument and related disposables to the University Hospital of Würzburg, one of the leading national hospitals in Germany.

Milestone Scientific Inc. Commences Sales of CompuFlo® Epidural Instruments and Disposables to University Hospital of Würzburg in Germany

Milestone Scientific Inc (NYSEAMERICAN:MLSS) reported that it has signed three additional distribution agreements in the US and one in Canada for the company's Wand Single Tooth Anesthesia (STA) System. With Monday's announcement, Milestone Scientific noted that it has added eight independent North American distributors in less than one month.

Milestone Scientific adds four new North American distributors for its Wand Single Tooth Anesthesia System

Brings network to eight independent North American distributors in under one month Brings network to eight independent North American distributors in under one month

Milestone Scientific Adds Three Additional Premier Distributors Providing Robust U.S. Coverage and a New Distributor in Canada for the Company's Dental Instrument

ROSELAND, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug instruments that provide painless and precise injections, announced that it will be presenting at the Winter Wonderland Conference, hosted by The MicroCap Rodeo, being held virtually on February 16th - February 19th, 2021.

Milestone Scientific to Participate in the Winter Wonderland Conference- Best Ideas from the Buy-Side

Milestone Scientific Inc (NYSEAMERICAN:MLSS) announced Tuesday that it has signed two additional distribution agreements with Atlanta Dental and Nashville Dental for its Wand Single Tooth Anesthesia (STA) System.   Atlanta Dental and Nashville Dental are leading distributors of dental products in the US, headquartered in Georgia and Tennessee, respectively.

Milestone Scientific signs distribution deals with Atlanta Dental and Nashville Dental for its Wand Single Tooth Anesthesia System

Adds four independent U.S. distributors in under one month

Milestone Scientific Continues Expansion of Distributor Network for Dental Instrument in the US; Adds Two Additional Independent Distributors Covering Atlanta and Tennessee

MLSS has an exciting technology for computerized drug delivery which should dramatically cut costs and improve patient outcomes. The technology uses sensors to pinpoint the type of tissue into which drugs are optimally injected.

Milestone Scientific: Poised For A Long Uptrend

ROSELAND, N.J., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent relating to the disposable component of Milestone's CompuFlo® Instrument.

Milestone Scientific Inc. Receives Notice of Allowance for U.S Patent Related to CompuFlo® Disposables

Agreements have been put into place with two distributors covering Florida, New York and New Jersey

Milestone Scientific Inc. Announces It has Begun Implementing Three-Year Strategy to Expand the World-Wide Global Dental Market

ROSELAND, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today raised revenue guidance to over $2 million for the fourth quarter of 2020, a 67% sequential increase over $1.2 million reported for the third quarter of 2020.

Milestone Scientific Inc. Raises Revenue Guidance to Over $2 Million for Q4 2020

Milestone's FDA approved CompuFlo and CathCheck instruments and disposables provide significant safety and economic benefits Milestone's FDA approved CompuFlo and CathCheck instruments and disposables provide significant safety and economic benefits

Milestone Scientific Inc. Announces Entrée into the Nationally Recognized University of Texas Medical Branch at Galveston with its CompuFlo Disposables

ROSELAND, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today reported that the Company's Interim CEO, Leonard Osser, plans to exercise up to 336,970 options. In connection with the transaction, he plans to sell a portion of his shares to cover the cost of the options and associated taxes. However, the net impact of the transaction will be an increase in Mr. Osser's overall common stock holdings. Mr. Osser has no plans to sell additional shares.

Milestone Scientific Inc. CEO to Increase Stock Ownership through Option Exercise

MLSS's dental business has almost fully recovered from the pandemic lows, with several tailwinds on the horizon. MLSS progressed its medical side of the business significantly in early Q4 with the announcement of an agreement with Premier, a large group purchasing organization.

Milestone Wins Could Lead To A Breakout

Anticipates over 40% sequential increase in sales for Q4 2020 versus Q3 2020 Anticipates over 40% sequential increase in sales for Q4 2020 versus Q3 2020

Milestone Scientific Inc. Reports Continued Growth in Dental Sales

Milestone Scientific, Inc. (MLSS) CEO Leonard Osser on Q3 2020 Results - Earnings Call Transcript

ROSELAND, N.J., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the third quarter and nine months ending September 30, 2020.

News for Milestone Scientific Stock (MLSS)